IDEAYA collaborates with Gilead for Phase 1 combo of IDE397 + Trodelvy in MTAP-deletion bladder cancer

IDEAYA Biosciences, Inc.

IDEAYA and Gilead will evaluate IDE397 (MAT2A inhibitor) plus Trodelvy (Trop-2 ADC) in MTAP-deletion bladder cancer.
MTAP-deletion prevalence in bladder cancer is ~26%, with no approved therapies for this population.
IDEAYA sponsors the Phase 1 trial; Gilead provides Trodelvy at no cost; each party retains commercial rights to its own compound.
IDEAYA is also evaluating IDE397 in an ongoing Phase 1/2 monotherapy and in a separate Amgen combination study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.